repurposing semaglutide and liraglutide for alcohol use disorder Associations of with incidence recurrence of in real-world population Obesity-fighting drugs may reduce alcohol

F., Peng, Y., Hou, W

At the higher doses, results were very consistent: All participants lost at least 5% of their body weight Around 3 in 4 lost 15% or more With placebo, only around 1 in 4 lost 5% or more Phase 3 update (TRIUMPH-4, 68 weeks, topline results) In December 2025 , Eli Lilly shared early (topline) results from a larger phase 3 study (TRIUMPH-4)

Rebalancing their bodys natural hormone levels

doi: 10.1038/sj.bjp.0707395 68 GluvicZMObradovicMMSudar-MilovanovicEMZafirovicSSRadakDJEssackMMet al

Cardiovascular Benefits: Recent studies suggest that GLP-1 receptor agonists may provide cardiovascular benefits

A clear sign of tolerance development